BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.

AI/ML

Biotechnology

Pharmaceutical

Therapeutics

BigHat Bio

Mark DePristo

Vi Vu

Abiy Seifu

John Corbin

Mitchell Stieg

Leslie Grab

Danielle Landrein

Timothy Park

Charbel Eid

Eddie Abrams

Liz Schwarzbach

Peyton Greenside

The Research and Development team at BigHat Bio spearheads innovative projects to advance antibody therapeutics. This team leverages the company's AI-enabled experimental platform to accelerate the design and optimization of next-generation antibodies, facilitating the creation of safer and more effective treatments for complex diseases. Team members collaborate closely to integrate high-speed lab data with machine learning technologies, driving forward BigHat's mission to revolutionize human health.

Research and Development

Research Team

Software Development Team

Advisory Team

Research and Development

About

Team members

Other teams at BigHat Bio

Research Team

Software Development Team

Advisory Team